Miscellaneous
188 Urology Journal Vol 7 No 3 Summer 2010
Safety and Efficacy of Clomiphene Citrate and
L-Carnitine in Idiopathic Male Infertility
A Comparative Study
Mahmoudreza Moradi,1 Asaad Moradi,1 Mohsen Alemi,1 Hassan Ahmadnia,2
Hossein Abdi,1 Alireza Ahmadi,3 Shahrzad Bazargan-Hejazi4
Purpose: To compare the effects of L-carnitine with clomiphene citrate in
idiopathic infertile men.
Materials and Methods: Fifty-two men with idiopathic infertility were
recruited in this randomized controlled trial. They were randomly assigned
into 2 treatment groups, group 1 (n = 20) and group 2 (n = 32), who received
L-carnitine 25 mg/day and clomiphene citrate 2 gr/day, respectively, for a
period of 3 months.
Results: Comparing the effect of L-carnitine and clomiphene on sperm
parameters before and after the treatment, both medications had influence
on sperm count and motility (P = .01). L-carnitine significantly increased
the semen volume (P = .001), while clomiphene citrate was significantly
associated with the motility percentage and normal morphology (P = .008).
Conclusion: It seems that the use of clomiphene citrate and L-carnitine,
either individually or in combination, as the first step of idiopathic male
infertility treatment is reasonable, safe, and effective.
Urol J. 2010;7:188-93.
www.uj.unrc.ir
Keywords: semen parameters, male
infertility, randomized controlled trial
1Fertility-Infertility Research Center,
Urology and Nephrology Research
Center, Imam Reza Hospital,
Kermanshah University of Medical
Sciences, Kermanshah, Iran
2Department of Urology, Mashhad
University of Medical Sciences,
Mashhad, Iran
3Department of Anesthesiology,
Imam Reza Hospital, Kermanshah
University of Medical Sciences,
Iran-Department of Public Health
Sciences, Division of Social
Medicine, Karolinska Institute,
Stockholm, Sweden
4Department of Psychology,
College of Medicine, Charles Drew
University of Medicine and Science,
David Geffen School of Medicine,
UCLA, Los Angeles, CA, USA
Corresponding Author:
Mahmoudreza Moradi, MD
Fertility-Infertility Research Center,
Imam Reza Hospital, Kermanshah
University of Medical Sciences, Iran
Tel: +98 918 132 4811
Fax: +98 831 725 9983
E-mail: drmrmoradi@yahoo.com
Received July 2009
Accepted November 2009
INTRODUCTION
Infertility is considered as one of
the most important issues among
married couples. According to the
current statistics, about 15% of
married couples face with infertility
at the end of the first year of
their marriage, with male gender
implicated in 20% of these cases.
Other evidence shows that in 30%
to 40% of infertile cases, both man
and woman play a role.(1) A male
factor, therefore, plays a 50% role
in the etiology of infertility.(2)
Idiopathic male infertility (IMI),
with a prevalence of approximately
25%, is a condition where abnormal
semen parameters are obtained
due to non specific causes. In the
majority of cases, abnormal semen
parameters leads to diagnosis
of oligoasthenoteratospermia,
and in others, it leads to
isolated abnormalities of sperm
concentration, motility, and
morphology. Due to the lack
of differentiable or correctable
etiology, patients with IMI are
often treated by varieties of
empirical medications or assisted
reproductive technologies.
However, the meta-analysis of
controlled trials on patients with
IMI has revealed that, with a few
exceptions, the majority of the
trials failed to show the efficacy of
treatments. Yet, due to obtained
success among small number of
Clomiphene and/or Carnitine for Male Infertility—Moradi et al
189Urology Journal Vol 7 No 3 Summer 2010
patients with IMI, efforts in medication therapy
and technology assisted management of IMI
continue.(2)
Clomiphene citrate, as an anti-estrogen, is
the most common prescribed medication for
male infertility. However, L-carnitine, which
is known to improve semen’s parameters, has
recently been recognized as the most effective
medication. L-carnitine molecule controls the
transport of acetyl and acyl groups across the
mitochondrial inner membrane and is an essential
agent for mitochondrial metabolism. Although
the exact function of L-carnitine and acetylated
carnitine in the epididymis, where these agents
are found in high concentration, is not entirely
known, but they seem to have a protective ability
against oxidative damages. Both L-carnitine
and L-acetyl-carnitine are available as over-the-
counter medications in the form of nutritional
supplements for the treatment of IMI.(2)
The anti-estrogenic role of clomiphene citrate and
the therapeutic role of L-carnitine in treatment
of infertility are well documented;(3-7) however,
literature reveals a paucity of research comparing
treatment outcome of clomiphene citrate and
L-carnitine in infertile men.
The specific aim of this study was to compare
treatment outcome of L-carnitine with the
standard treatment, clomiphene citrate, in
infertile men with oligoasthenoteratospermia.
MATERIALS AND METHODS
This randomized longitudinal study was carried
out on 107 patients who presented with idiopathic
infertility to the urology clinics of Kermanshah
University of Medical Sciences between January
2006 and January 2008.
Of 107 patients, those who met the following
inclusion criteria of: 1) a history of infertility
for at least one year 2); and semen parameter
abnormalities, including sperm concentration
or count less than 20 × 106 spermatozoa/mL,
motility less than 50% with grade “a + b” or 25%
with grade “a”, and morphology less than 50%,
for which no specific causes were identified, were
enrolled in this study. Then, a written informed
consent was obtained from each patient.
On the other hand, patients who presented with
symptoms of hypogonadism or sperm count
less than 10 million/mL, and/or any hormonal
disorder detected by hormonal tests, including
testosterone, prolactin, luteinizing hormone (LH),
and follicle-stimulating hormone (FSH) were
excluded from the study. Furthermore, patients
with an inguinal operation, infectious or venereal
diseases, testicular atrophy, hypogonadism,
varicocele, and disorders of the vas deferens and
the epididymis were also excluded from the study.
The study protocol was approved by the ethics
committee of Kermanshah University of Medical
Sciences.
The remaining 52 patients were randomly
assigned into 2 groups in a double blind manner
by the sealed opaque envelope technique; group
1 (n = 20) and group 2 (n = 32) who received
clomiphene citrate 25 mg/day (Tab. 50 mg/Iran
Hormone Co.) and L-carnitine 2 gr/day (Tab. 250
mg/Shahre Daru Co.), respectively, for 3 months.
Post treatment semen analyses were performed
twice, within a window period of 5 days, for
all the subjects who completed the 3-month
treatment, to increase the accuracy of the test
results and reduce test bias.
The mean score for semen parameters analysis
was calculated for each participant in both
treatment groups. Using paired sample t test,
parameters, including sperm count, semen
volume, motility, and morphology were
compared between two groups before and after
the treatment assignments.
Using an independent sample t test, post
treatment semen measures of the subjects in both
treatment groups were compared with each other.
These tests allowed us to see if there were any
detectable differences between the means of the
study measures between and across the groups,
and if the differences were statistically significant.
All statistical analyses were performed using SPSS
software (Statistical Package for the Social Science,
version 14.0, SPSS Inc, Chicago, Illinois, USA).
RESULTS
The mean age of the patients was 28.46 ± 2.67
years (range, 22 to 35 years). Of a total of 52,
Clomiphene and/or Carnitine for Male Infertility—Moradi et al
190 Urology Journal Vol 7 No 3 Summer 2010
32 patients with the mean age of 28.44 ± 2.34
years (range, 22 to 35 years) and 20 patients with
the mean age of 28.5 ± 3.21 years (range, 26 to
31 years) were treated by clomiphene citrate
and L-carnitine, respectively. The mean period
of infertility was 2.98 ± 4.11 years (range, 1 to
14 years) for all the patients; 3.12 ± 3.52 years
(range, 1 to 7 years) in clomiphene citrate group
and 2.87 ± 4.7 years (range, 1 to 14 years) in
L-carnitine group.
Table compares changes of the semen parameters
before and after the treatment with clomiphene
citrate and L-carnitine. In clomiphene citrate
group, the average values of semen volume,
sperm counts, motility percentage, and normal
morphology before the treatment were 3.21
± 1.3 mL, 20.38 ± 16.2 million/mL, 23.78 ±
17.5%, and 45.06 ± 20.8%, respectively, which
changed to 3.36 ± 1.3 mL, 42.51 ± 29.4 million/
mL, 43.38 ± 20.1%, and 58.44 ± 19.3% after the
treatment. Our results revealed that clomiphene
citrate had considerable influence on sperm count,
morphology, and motility (P = .01), but not
much effect on the semen volume (P = .57).
In L-carnitine group, the average values of semen
volume, sperm counts, motility percentage, and
normal morphology before the treatment were
2.50 ± 1.2 mL, 44.75 ± 18.1 million/mL, 38.82
± 15.5%, and 48.40 ± 37.9%, respectively. After
the treatment, these parameters altered to 4.03 ±
0.8 mL, 73.25 ± 18.5 million/mL, 48.03 ± 19.7%,
and 49.45 ± 32.2%. There was a statistically
significant association between L-carnitine
and semen volume, sperm count, and motility
(P = .01), but not with the sperm morphology
(P = .698).
Comparing the effect of L-carnitine and
clomiphene on sperm parameters before and
after the treatment, both had influence on
sperm count and motility (P = .01). The effect
on sperm counts was not significant (P = .376).
L-carnitine significantly increased the semen
volume (P = .001), while clomiphene citrate
was significantly associated with the motility
percentage and normal morphology (P = .008).
DISCUSSION
Clomiphene citrate is one of the most common
experimental medications used for treatment
of idiopathic infertility. As an anti-estrogen,
clomiphene citrate links to the receptors of
estradiol in the hypothalamus and stimulates the
gonadotropin secretion. Anti-estrogens increase
the pituitary gonadotropin secretion by blocking
feedback inhibition, thus, increasing both serum
FSH and LH levels as well as the testicular
production of testosterone. Clomiphene citrate
with the dosage of 25 mg per day is the standard
recommended treatment for IMI. Higher doses of
clomiphene citrate, however, may cause down-
regulation of the system.(1,2)
In the present study, we anticipated noticing
an overall improvement in the sperm count,
semen volume, motility percentage, and
morphology in the group receiving L-carnitine
P
L-CarnitineClomiphene Citrate
Parameters
After TreatmentBefore TreatmentAfter TreatmentBefore Treatment
= .01*
= .01†
= .376‡
73.25 ± 18.544.75 ± 18.142.51 ± 29.420.38 ± 16.2Sperm Count
= .57*
= .01†
= .001‡
4.03 ± 0.82.50 ± 1.23.36 ± 1.33.21 ± 1.3Semen Volume
= .01*
= .01†
= .008‡
48.03 ± 19.738.82 ± 15.543.38 ± 20.123.78 ± 17.5Motility
= .01*
= .698†
= .008‡
49.45 ± 32.248.40 ± 37.958.44 ± 19.345.06 ± 20.8Morphology
Comparison between changes of the semen parameters before and after the treatment with clomiphene citrate and L-carnitine
*Clomiphene citrate
†L-carnitine
‡Comparison of two drugs with each other
Clomiphene and/or Carnitine for Male Infertility—Moradi et al
191Urology Journal Vol 7 No 3 Summer 2010
compared to the group that received clomiphene
citrate. Comparing baseline measures of semen
parameters with that of the follow-ups, our data
showed an increase in the sperm motility and
count in both groups; clomiphene citrate and
L-carnitine (P = .01). However, no meaningful
association was observed between semen volume
and clomiphene citrate (P = .57) as well as
morphology and L-carnitine (P = .698). This
finding is not compatible with the finding of
Mićić and colleagues.(8) They randomly divided
101 patients with a history of 2-year infertility
into 2 groups. Fifty-six patients received 50 mg/
day clomiphene citrate for 6 to 9 months and
45 patients as the control group received no
medication. In that study, sperm parameters such
as semen volume and sperm motility were treated
with clomiphene citrate compared to the control
group (P ≤ .05).(8)
Khademi and coworkers studied 48 smokers
and 122 non-smokers with abnormal sperms
after receiving L-carnitine 3 times per day for
3 months. They observed that L-carnitine was
effective in improving sperm mobility percentage,
grade A sperms, and normal-shaped sperms.
Improvements in the non-smokers were even
more noticeable. They concluded that a smoker
should not be excluded from the treatment with
L-carnitine.(6)
In the study by Cavallini and colleagues,(7) the
effect of cinnoxicam supplement and L-carnitine
on idiopathic infertility and varicocele was
examined in 3 groups: placebo group; L-carnitine
(2 gr/day) + acetyl-L-carnitine (1 gr/day) group;
and L-carnitine + cinnoxicam (30 mg) group.
After 6 months, sperm count, sperm motility and
morphology, the amount of fertility (pregnancy
rate), and complications were recorded. In
placebo group, no change was observed in sperm
parameters. In the group that received L-carnitine
+ acetyl-L-carnitine, sperm parameters increased
significantly at 3 and 6 months in idiopathic
infertile patients with minor varicoceles, but
no improvement was observed in idiopathic
infertile patients with severe varicoceles. But all
the patients in group 3 had significantly increased
sperm parameters with the exception of very
severe varicoceles. Pregnancy rates were 1.7%
(group 1), 21.8% (group 2), and 38.0% (group 3)
(P ≤ .01). Cavallini and colleagues concluded that
combination of L-carnitine and cinnoxicam could
be a reliable treatment for low-grade varicoceles
and idiopathic oligoasthenospermia.(7)
In spite of positive effect of L-carnitine on
sperm motility in the present study, Sigman
and colleagues did not find such statistically
significant association.(9) Sigman and coworkers
compared the effects of L-carnitine, ie, 2000
mg/day L-carnitine and 1000 mg/day L-acetyl-
carnitine for 24 weeks, with placebo on idiopathic
asthenospermic patients. Sperm motility and the
number of mobile sperms were measured at the
baseline, 12 weeks, and 24 weeks post treatment.
No statistically or clinically significant differences
were found between the two groups at any of the
measured points.(9)
However, our results regarding the effect of
clomiphene citrate and L-carnitine on the sperm
count and sperm motility are consistent with
several studies.(3-7) In the study by Patankar and
colleagues,(3) clomiphene citrate 25 mg/day was
administered for 2 groups for 25 days, including
5 days resting period for duration of 3 months.
First group included 25 men with extreme
oligospermia and the second group composed of
40 men with moderate oligospermia. Results of
seminal fluid analysis at the end of the treatment
period were as follows: the mean sperm count
in the first and second group increased from
3.84 to 8.2 million/mL and from 13.05 to 24.55
million/mL, respectively. The mean motile
sperms in the first group increased from 1.74 to
3.92 and in the second group from 8.27 to 10.05.
The researchers concluded that the medication
was more effective when there was no end-organ
pathology.(3)
Zhou and associates in a systematic review of
9 studies reported the effects of L-carnitine on
male infertility. The meta-analysis compared
L-carnitine and/or L-acetyl-carnitine therapy
with placebo treatment. They found significant
improvement in pregnancy rate, total sperm
motility, forward sperm motility, and atypical
sperm cell.(5) In a study including 30 men with
oligospermia, Rönnberg observed that in the
group who received clomiphene citrate 50 mg
Clomiphene and/or Carnitine for Male Infertility—Moradi et al
192 Urology Journal Vol 7 No 3 Summer 2010
per day for 3 months, the average sperm count
increased from 13.3 to 28.5 million/mL (P ≤ .05).
Moreover, in clomiphene citrate group, 3 cases
of pregnancy were observed; while none were
observed in the control group.(4)
Still others claim that there is yet no acceptable
empirical treatment for IMI. (9-11) Reviewing 20
years of medication therapies for IMI, Kumar
and colleagues found no clear advantage for
any of the medications used by the patients. (11)
Vandekerckhove and associates reviewed 10
studies consisting of 738 infertile men, to evaluate
the effect of anti-estrogens like clomiphene citrate
and tamoxifen on idiopathic oligoasthenospermia.
They concluded that anti-estrogens appeared to
have a beneficial effect on endocrines, but there
was not enough evidence to evaluate the use of
anti-estrogens for increasing the fertility of men
with idiopathic oligoasthenospermia.(10)
Limitations and Future Directions
We view this to be an incipient project and
recognize its limitations. Small sample size with
limited statistical power, lack of placebo group,
failing to consider pregnancy rate as the ultimate
measure of treatment outcome, and short-term
follow-up period (3 months) were the flaws of this
study. However, to the best of our knowledge,
it is amongst the first studies that has compared
the effect of clomiphene citrate and L-carnitine
regarding semen parameters abnormalities in
idiopathic infertile men.
L-carnitine in this study had a significant effect
on improving semen parameters; it has few side-
effects and seems to be an appropriate choice
for idiopathic infertile men when taken in
combination with clomiphene citrate. Therefore,
findings of this study are encouraging enough
to stimulate further similar investigations to
expand our findings with the use of larger
samples, inclusion of placebo/control group, and
consideration of pregnancy rates as the ultimate
treatment outcome measure.
CONCLUSION
Clomiphene citrate and L-carnitine are among
the most administered, available, and effective
medications for male infertility, while offering
fewer complications. Results of this study suggest
that the treatment outcome of clomiphene
citrate and L-carnitine on the sperm count is
nearly equal. However, the effect of L-carnitine
on the semen volume is more meaningful
than clomiphene citrate (P = .001) and the
effect of clomiphene citrate on motility and
morphology is more meaningful than L-carnitine
(P = .008). It seems that the use of clomiphene
citrate and L-carnitine, either individually or
in combination, as the first step of idiopathic
male infertility treatment is reasonable, safe, and
effective.
ACKNOwLEDGEMENT
The authors would like to thank all who
participated in this study. Financial support
for this project was provided by Kermanshah
University of Medical Sciences.
CONFLICT OF INTEREST
None declared.
REFERENCES
1. Guyton AC, Hall JE. Textbook of Medical Physiology.
Philadelphia: wB Saunders; 2000:996-1009.
2. Sigman M, Jarow JP. Male Infertility. In: wein AJ,
Kavoussi LR, Novick AC, Partin Aw, Peters CA, eds.
Campell-walsh Urology. Vol 1. Philadelphia: Saunders
2007:609-53.
3. Patankar SS, Kaore SB, Sawane MV, Mishra NV,
Deshkar AM. Effect of clomiphene citrate on sperm
density in male partners of infertile couples. Indian J
Physiol Pharmacol. 2007;51:195-8.
4. Rönnberg L. The effect of clomiphene citrate on
different sperm parameters and serum hormone levels
in preselected infertile men: a controlled double-blind
cross-over study. Int J Androl. 1980;3:479-86.
5. Zhou X, Liu F, Zhai S. Effect of L-carnitine and/
or L-acetyl-carnitine in nutrition treatment for male
infertility: a systematic review. Asia Pac J